Morgan Stanley analyst Yuko Oku maintained a Hold rating on GRAIL Inc today and set a price target of $38.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yuko Oku has given his Hold rating due to a combination of factors that reflect both the potential and the risks associated with GRAIL Inc. While the company shows promising long-term prospects with its Galleri multi-cancer early detection test, there are significant challenges related to regulatory approvals and reimbursement pathways. The upcoming NHS-Galleri data in mid-2026 is crucial for gaining physician support and advancing discussions with payors, which adds uncertainty in the near term.
Despite the positive developments such as higher screening revenue and reduced cash burn, the stock is expected to remain range-bound until key milestones, like the NHS-Galleri readout and FDA submission, are achieved in the next 12-24 months. The company’s current valuation, based on a discounted cash flow analysis, suggests a potential for higher valuation in the long term, but the stock’s performance is likely to be constrained by its early commercial stage compared to more established peers. Therefore, Yuko Oku remains cautious, maintaining a Hold rating with a price target of $38.
In another report released on July 30, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $35.00 price target.